Search research articles
Contact Us
Filters
Showing results (31-40 of 67) with videos related to
Page
of 7
Sort By:
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
September 1, 2021
Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial
Charles S Fuchs, Mustafa Özgüroğlu, Yung-Jue Bang, et al.
The New England Journal of Medicine
|
June 20, 2024
Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
Georgina V Long, Axel Hauschild, Mario Santinami, et al.
The Lancet. Oncology
|
March 26, 2018
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
Reinhard Dummer, Paolo A Ascierto, Helen J Gogas, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 28, 2024
Immunotherapy or targeted therapy with or without stereotactic radiosurgery for patients with brain metastases from melanoma or non-small cell lung cancer - The ETOP 19-21 USZ-STRIKE study
Michael Weller, Emilie Le Rhun, Lydia Tsamtsouri, et al.
The Lancet. Oncology
|
September 17, 2018
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
Reinhard Dummer, Paolo A Ascierto, Helen J Gogas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 15, 2026
Exploratory Analysis of Biomarkers and Treatment Outcomes From the COLUMBUS Study in BRAF V600E/K-Mutant Advanced or Metastatic Melanoma
Reinhard Dummer, Shibing Deng, Tao Xie, et al.
The Lancet. Oncology
|
March 13, 2017
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial
Reinhard Dummer, Dirk Schadendorf, Paolo A Ascierto, et al.
The Lancet. Oncology
|
August 15, 2024
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
Emanuel Bührer, Michal Kicinski, Mario Mandala, et al.
Nature Medicine
|
September 24, 2025
Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial
Georgina V Long, Nitya Nair, Daniel Marbach, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 25, 2019
Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)
Paul Nathan, Paolo A Ascierto, John Haanen, et al.
Page
of 7
Search research articles
Search
Showing results (31-40 of 67) with videos related to
Sort By:
Page
of 7
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
September 1, 2021
Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial
Charles S Fuchs, Mustafa Özgüroğlu, Yung-Jue Bang, et al.
The New England Journal of Medicine
|
June 20, 2024
Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
Georgina V Long, Axel Hauschild, Mario Santinami, et al.
The Lancet. Oncology
|
March 26, 2018
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
Reinhard Dummer, Paolo A Ascierto, Helen J Gogas, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 28, 2024
Immunotherapy or targeted therapy with or without stereotactic radiosurgery for patients with brain metastases from melanoma or non-small cell lung cancer - The ETOP 19-21 USZ-STRIKE study
Michael Weller, Emilie Le Rhun, Lydia Tsamtsouri, et al.
The Lancet. Oncology
|
September 17, 2018
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
Reinhard Dummer, Paolo A Ascierto, Helen J Gogas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 15, 2026
Exploratory Analysis of Biomarkers and Treatment Outcomes From the COLUMBUS Study in BRAF V600E/K-Mutant Advanced or Metastatic Melanoma
Reinhard Dummer, Shibing Deng, Tao Xie, et al.
The Lancet. Oncology
|
March 13, 2017
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial
Reinhard Dummer, Dirk Schadendorf, Paolo A Ascierto, et al.
The Lancet. Oncology
|
August 15, 2024
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
Emanuel Bührer, Michal Kicinski, Mario Mandala, et al.
Nature Medicine
|
September 24, 2025
Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial
Georgina V Long, Nitya Nair, Daniel Marbach, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 25, 2019
Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)
Paul Nathan, Paolo A Ascierto, John Haanen, et al.
Page
of 7